Biotech groups file the second lawsuit against Medicare's international drug price pilot
BIO and two California trade groups asked a federal court on Friday to throw out the GLOBE model, which from January ties Medicare Part B rebates on certain drugs to prices in 19 other countries.

The Biotechnology Innovation Organization (BIO), California Life Sciences and Biocom California filed suit on Friday in the US District Court for the Northern District of California to block the Global Benchmark for Efficient Drug Pricing (GLOBE) model, a mandatory Medicare payment test that starts January 1, 2027. The complaint1 asks the court to declare the model unlawful, vacate it and stay its effective date. It is the second industry suit against the model, after the Pharmaceutical Research and Manufacturers of America (PhRMA) sued in Washington on October 7.
GLOBE is the Trump administration's attempt to bring foreign drug prices into Medicare's payment for infused and injected drugs. Under the final rule4, published October 2, manufacturers of covered drugs owe Medicare a rebate when the drug's US price exceeds a benchmark built from the lowest price in 19 reference countries, including Canada, Germany, Japan and the United Kingdom. Beneficiary coinsurance on those drugs is tied to the benchmark as well. The model applies in geographic areas chosen to cover about 25% of Original Medicare Part B enrollees and covers single-source drugs and sole-source biologics with more than $100 million a year in Original Medicare Part B spending.
What is at stake for what people pay
For people on Original Medicare, the stakes are specific but, by CMS's own count, small. The final rule estimates the model will save $440 million in Medicare Part B net spending over its seven-year payment period, against total Original Medicare Part B drug spending of $81.90 billion in 2025. Beneficiaries would save an estimated $111 million in all: $50 million in coinsurance and $61 million in Part B premiums, according to the rule's impact analysis.
Those figures are far below what CMS projected a year ago. The proposed rule estimated $8.4 billion in Original Medicare Part B savings over the payment period and $1.4 billion in beneficiary premium savings. The comparable figures in the final rule are $298 million and $111 million. CMS attributes much of the drop to its assumption that manufacturers that signed agreements under its voluntary GENEROUS model by August 17, 2026 will be waived out of GLOBE, and to drugs it removed from the model after public comments.
The trade groups seize on that math. Their complaint says CMS did not dispute commenters' estimate that only about 0.3% of beneficiaries would see any change in what they pay. BIO's press release2 says the three groups represent more than one-third of US biotech companies.
The legal claims
The complaint raises three counts. The first says the rule exceeds the authority Congress gave CMS's Innovation Center under section 1115A of the Social Security Act to test payment models, and instead rewrites the Part B inflation rebate statute. The second says it violates the Appropriations Clause and related statutes. The third says it violates separation of powers and nondelegation principles. Joe Franklin, BIO's chief legal and policy officer, said in the release that CMS "crossed the limits Congress placed on its authority."
PhRMA's complaint6, filed in the US District Court for the District of Columbia, makes two claims, that GLOBE is contrary to law and that it violates the Constitution, and also asks the court to vacate the rule. CMS did not immediately respond to a request for comment from STAT3, which first reported the BIO filing on Saturday.
How the model got here
The final rule takes effect November 30, 2026. It describes GLOBE as a test of an alternative way to calculate the Part B drug inflation rebate, run through the Innovation Center, whose model-testing authority is the legal footing both lawsuits attack. Covered drugs come from oncology, rheumatology, immunology, ophthalmology and endocrinology, with exceptions, according to the CMS model page5.
What comes next
Data collection under GLOBE starts January 1, 2027. The five performance years run from April 1, 2027 to March 31, 2032, and that April date is when beneficiaries in the selected areas would first see lower coinsurance. Rebate invoicing and reconciliation run through March 31, 2034. Neither court has set a hearing date in the pages reviewed for this article. The question for the next eight weeks is whether either court stays the rule before the January start, which would leave Part B payment and the 20% coinsurance on these drugs tied to US prices for now.



